Introduction
============

Cancer registration is a method of systematically and continuously collecting cancer data, including demographic, diagnostic, treatment, and outcome information (Moore, 2013). Accurate, complete, and timely cancer registry data could serve as useful information for assessing cancer incidence, monitoring and evaluation of the national cancer control program, as well as cancer research (Bray and Parkin, 2009).

After the Korea Central Cancer Registry (KCCR) project was launched in 1980, the Korea National Cancer Incidence Database was established in South Korea in 1999 and has served as a foundation for national cancer statistics, from the calculation of cancer incidence to the assessment of survival and prevalence. Internationally, quality of cancer incidence statistics of Korea have been recognized by their inclusion in the "Cancer Incidence in Five Continents" volumes IX (2007), X (2013), and XI (2017) (http://ci5.iarc.fr/Default.aspx) published by the International Agency for Research on Cancer.

The World Health Organization suggests national cancer monitoring systems to measure the national and local cancer burden, socioeconomic differences, costs, individual and biological factors, and health behaviors, but many of these items are difficult to identify or collect (Ryerson and Massetti, 2017). As such, the cancer registries of Korea also have shortcomings in the collection of information about treatment and its outcomes (Soon et al., 2013). Therefore, continuous efforts to expand the scope of registry and items are essential to addressing the limitations of the national cancer registry data and to increase their usefulness. To this end, the KCCR has added the stage variable according to the Surveillance Epidemiology and End Results (SEER) summary stage. Additionally, collaborative staging (CS) information for four cancers (stomach, colon, breast, and uterine cervix), the path of diagnosis, laterality, differentiation, and site of metastasis has also been collected since 2012.

Multiple aspects must be considered to expand the cancer registration items. First, we must consider whether the information can be drawn from medical records and whether the relevant information could be collected for all cancers and from all hospitals. Moreover, accurate information should be collected via standardized guidelines, computer programs, and education for data abstractors (medical record administrators \[MRAs\]).

Thus, this study aimed to investigate the additional cancer registration items that could be collected by examining foreign cancer registries and large hospitals in Korea. Further, we assessed the need to expand items and the priority of the items in order to present potential cancer registry items to be added.

Materials and Methods
=====================

This study was conducted in three stages ([Figure 1](#F1){ref-type="fig"}). First, cancer registry items in five foreign registries and large hospitals in Korea were compared with those of the KCCR to identify items that could potentially be added to the KCCR database. Second, the identified items were surveyed among MRAs, who are the actual workers in charge of cancer registration in hospitals, to assess the need to collect these items and the priority of the items. Finally, the same items were presented to cancer experts to obtain information about essential items, the reason for selection, and the main areas of use. The methodology employed in this study was identical to that used in a study that investigated the need to collect data and factors hindering the utilization of the national program of cancer registries and clinical researchers in the United States (Zachary et al., 2015).

*Identification of potential cancer registry items by comparing foreign and domestic data*

We compared the cancer registry items in five foreign cancer registries and five hospital cancer registries with reference to the KCCR items ([Table 1](#T1){ref-type="table"}). Cancer registry items collected by the North American Association of Central Cancer Registries (NAACCR), National Health Services (NHS) Cancer Registration Dataset, European Network of Cancer Registries (ENCR), Japanese Association of Cancer Registries (JACR) and Cancer Council Australia (CCA) were categorized into demographic information, cancer diagnosis, treatment, staging and prognostic factors, and follow-up for comparison. In addition to the cancer registry items submitted to the KCCR by five large hospitals in Korea, we investigated and compared additional items collected by these hospitals.

*Identification of potential cancer registry items and analysis of their usefulness based on a consensus among cancer registration workers (MRAs) and cancer experts (researchers)*

We assessed the need to add items identified in foreign and domestic cancer registries to the KCCR, the priority of collection, the purpose of collection, and use of information in terms of developing a monitoring system, assessing cancer prevention and treatment effects, and utilizing data in cancer research. The survey was conducted among MRAs and cancer experts.

The results were structured such that they could rate the need for each additional cancer registry item on a three-point scale (highly needed, needed, not needed) and the priority of the items by numbering them. In addition, MRAs were also asked to write about additional items that were not included in the survey. The results of the need for each item were presented as the total number of responses and percentage for each scale. The results of the priority of the items were presented as the rank of each item in the corresponding category and its mean and standard deviation.

The results for cancer experts were structured such that they could rate the priority of each cancer registry item under each category and the purpose of collecting data for each item. Further, the cancer experts were asked to provide suggestions to enhance the usefulness of cancer registry data. The items and contents of the results were reviewed, modified, and validated by four investigators and participating researchers from the KCCR. The survey was conducted among 500 MRAs and 36 cancer researchers who were members of the subcommittee for the Third-Term Comprehensive Plan for Cancer Control.

###### 

Items Collected in the Korea Central Cancer Registry

  Category                         Items
  -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Demographic information          Hospital number, patient registration number, resident registration number, name, sex, age, foreign citizen, homeless patient, occupation, address, zip code
  Cancer diagnosis                 Date of initial diagnosis, path of diagnosis, primary site code, area of primary cancer, laterality, morphology code, grade, method of diagnosis, date of admission, date of discharge
  Cancer treatment                 Application of treatment, type of treatment (surgery, chemotherapy, radiation, immune, hormone)
  Staging and prognostic factors   Staging (SEER code required, other staging information may be added), site of metastasis (enter site of metastasis at the time of diagnosis)
  Follow-up\*                      Date of expiration, cause of death
  Management information           Century of born, year of data, date of data entry, name of person who entered data, medical record administrator's license No.

\*, Enter if the patient was dead at the time of registration

###### 

Comparison of Cancer Registry Items by Country (Excluding Management information)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sources                                                                  Demographic information   Cancer\     Treatment   Staging and\         Follow-up          Total
                                                                                                     diagnosis               prognostic factors                      
  --------- -------------------------------------------------------------- ------------------------- ----------- ----------- -------------------- ------------------ -------
  KCCR      Korea Central Cancer Registry (Korea)                          11                        9           2           2                    2                  26

  NAACCR    North American Association of Central Cancer Registries (US)   83                        48          97          248                  80                 556

  NHS       National Health Services Cancer Registration Dataset (UK)      11                        9           20          31                   8                  79

  ENCR      European Network of Cancer Registries (EU)                     6                         19          6           18                   3                  52

  JACR      Japanese Association of Cancer Registries (Japan)              6                         8           9           1                    1                  25

  CCA       Cancer Council Australia (Australia)                           8                         11                      breast Selective     breast Selective   19
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Need for Potential CancerRegistry Items and Their Prioritization by Category (Survey among MRAs)

                                      Highly needed   Needed   Not needed   Missing   Priority                                 
  ----------------------------------- --------------- -------- ------------ --------- ---------- ------ ---- ----- ---- ------ -----
  Demographic information                                                                                                      
  Date of birth                       86              31.6     117          43.0      66         24.3   3    1.1   2    3.0    2.3
  Place of birth                      64              23.5     136          50.0      70         25.7   2    0.7   4    3.4    1.8
  Country of birth                    86              31.6     142          52.2      42         15.4   2    0.7   1    2.8    1.5
  Type of residence (urban/rural)     76              27.9     163          59.9      32         11.8   1    0.4   3    3.2    1.6
  Race                                78              28.7     146          53.7      47         17.3   1    0.4   5    3.6    1.7
  Ethnicity                           54              19.9     127          46.7      90         33.1   1    0.4   6    5      1.7
  Marital status at diagnosis         43              15.8     150          55.1      79         29     0    0.0   7    5.2    1.8
  Cancer diagnosis                                                                                                             
  Symptoms                            139             51.1     116          42.6      15         5.5    2    0.7   2    3.3    2.5
  Medical history                     147             54.0     112          41.2      10         3.7    3    1.1   1    3.3    2.3
  Smoking history                     155             57.0     109          40.1      6          2.2    2    0.7   6    4.6    2.6
  Date of multiple cancer diagnosis   140             51.5     108          39.7      21         7.7    3    1.1   4    4.1    2.1
  Concurrent cancer                   153             56.3     102          37.5      15         5.5    2    0.7   5    4.3    2.1
  Type of cancer                      166             61.0     90           33.1      14         5.1    2    0.7   3    3.5    2
  Date of specimen submission         79              29.0     122          44.9      64         23.5   7    2.6   8    7.1    2.1
  Type of specimen                    79              29.0     118          43.4      68         25     7    2.6   9    7.5    1.8
  Type of pathologic test             96              35.3     131          48.2      41         15.1   4    1.5   7    6.8    2.3
  Name of pathologist                 33              12.1     98           36.0      134        49.3   7    2.6   10   9.5    1.8
  Pathology laboratory                42              15.4     121          44.5      103        37.9   6    2.2   11   9.8    1.8
  Cancer treatment                                                                                                             
  Date of treatment                   131             48.2     110          40.4      29         10.7   2    0.7   1    2.6    2.2
  Treatment code                      121             44.5     112          41.2      35         12.9   4    1.5   2    3.4    2.2
  Radiation therapy                   116             42.6     112          41.2      39         14.3   5    1.8   4    3.6    1.7
  Chemotherapy                        121             44.5     118          43.4      27         9.9    6    2.2   3    3.6    1.8
  Palliative treatment                101             37.1     131          48.2      35         12.9   5    1.8   6    5.1    2.2
  Reason for non-treatment            74              27.2     140          51.5      53         19.5   5    1.8   7    6.1    2.2
  Treatment outcomes                  138             50.7     108          39.7      21         7.7    4    1.5   5    4.1    2.2
  30-day readmission                  70              25.7     133          48.9      65         23.9   4    1.5   8    6.8    2
  Follow-up care                      74              27.2     153          56.3      41         15.1   4    1.5   9    7.1    2.1
  Staging and prognostic factors                                                                                               
  Clinical TNM stage                  139             51.1     108          39.7      18         6.6    7    2.6   2    2.6    2.2
  Pathologic TNM stage                169             62.1     89           32.7      8          2.9    6    2.2   1    1.9    1.5
  TNM version                         108             39.7     125          46.0      30         11     9    3.3   3    4.2    2.3
  Pediatric cancer staging system     108             39.7     117          43.0      38         14     9    3.3   7    5.8    2.4
  Pre-treatment CS                    115             42.3     131          48.2      20         7.4    6    2.2   4    4.2    1.6
  Post-treatment CS                   117             43.0     124          45.6      25         9.2    6    2.2   5    5.0    1.6
  CS-site of metastasis               128             47.1     119          43.8      20         7.4    5    1.8   6    5.2    1.7
  CS-site-specific factor 1-25        91              33.5     127          46.7      46         16.9   8    2.9   8    7.0    1.6
  Comorbidity and complication 1-10   85              31.3     136          50.0      44         16.2   7    2.6   9    7.5    1.9
  Follow-up information                                                                                                        
  Date of final contact               67              24.6     128          47.1      67         24.6   10   3.7   4    4.9    3.2
  Age at final contact                60              22.1     125          46.0      77         28.3   10   3.7   6    6.0    3.4
  Facility of final contact           52              19.1     134          49.3      78         28.7   8    2.9   9    6.9    3.3
  Survival                            139             51.1     112          41.2      15         5.5    6    2.2   1    2.8    2.4
  Duration of survival                139             51.1     114          41.9      13         4.8    6    2.2   2    3.5    2.6
  Cancer state                        108             39.7     119          43.8      34         12.5   11   4     3    4.6    2.9
  Activities of daily living          54              19.9     145          53.3      64         23.5   9    3.3   8    6.7    2.9
  Follow-up information                                                                                                        
  Source of follow-up                 49              18.0     131          48.2      82         30.1   10   3.7   10   8.0    2.9
  Address at follow-up                41              15.1     126          46.3      94         34.6   11   4.0   11   9.3    3.0
  Date of initial recurrence          124             45.6     121          44.5      18         6.6    9    3.3   5    5.4    3.0
  Type of recurrence                  121             44.5     114          41.9      29         10.7   8    2.9   7    6.2    3.1
  Place of death                      57              21.0     116          42.6      91         33.5   8    2.9   12   10.2   3.1
  Autopsy                             41              15.1     131          48.2      88         32.4   12   4.4   13   10.4   3.1
  Physician in charge                 29              10.7     110          40.4      120        44.1   13   4.8   14   12.5   2.5

###### 

Potential Cancer Registry Items Identified by Cancer Experts

  -------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------------------------ -------------------------------------------------
  Category                                                 Required items                                         Major purpose                                                                        Main use

  Demographic information                                  Date of birth                                          Personal identification                                                              Alternative to resident registration number

  Race                                                     Foreigner identification                               Research on cancer trends in foreigners                                              

  Country of birth                                         Foreigner identification                               Research on cancer trends in foreigners                                              

  Place of birth                                           Identification of geographical factors                 Research on geographical/environmental associations with cancer                      

  Marital status at diagnosis                              Identification of cause of cancer                      Incidence and survival of particular cancers vary according to marital status        

  Cancer diagnosis                                         Type of Cancer (initial, recurrent)                    Classification of cancer                                                             Computation of recurrence rate

  Smoking history                                          Cause of specific cancer                               Identification of its association with specific cancer                               

  Date of multiple primary cancer diagnosis                Confirmation of multiple primary cancer                Multiple primary cancer has poor prognosis and requires a wider range of treatment   

  Concurrent cancer                                        Confirmation of unilateral organ                       Identification of cancer in unilateral organ                                         

  Medical history                                          Individual and family history related to cancer        Identification of factors related to cancer                                          

  Symptoms                                                 Symptoms related to specific cancer or asymptomatic    Identification of factors related to cancer                                          

  Type of pathologic test                                  Confirmation of reliability of diagnosis               Confirmation of reliability of diagnosis                                             

  Cancer treatment                                         Date of treatment                                      Collect detailed treatment information                                               Identify treatment efficacy

  Chemotherapy agent                                       Collect detailed treatment information                 Identify treatment efficacy                                                          

  Radiation therapy (type, dose, site)                     Collect detailed treatment information                 Identify treatment efficacy                                                          

  Treatment code                                           Collect detailed treatment information                 Identify treatment efficacy                                                          

  Palliative treatment                                     Collect information about palliative treatment         Identify efficacy of palliative treatment                                            

  Treatment outcomes (e.g., surgery)                       Collect information about post-treatment state         Identify treatment efficacy                                                          

  Reason for non-treatment                                 Policy-related management, such as treatment support   Identify treatment efficacy                                                          

  Staging and\                                             TNM stage (clinical, pathologic)                       Stage data                                                                           Determine staging and assess treatment efficacy
  prognostic factors                                                                                                                                                                                   

  CS (pre-treatment, post-treatment, site of metastasis)   Stage data                                             Determine staging and assess treatment efficacy                                      

  CS- site-specific factor                                 Stage data                                             Determine staging and assess treatment efficacy                                      

  Comorbidity and complication                             Stage data                                             Determine staging and assess patient survival and outcomes                           

  Follow-up information                                    Survival                                               Check for cancer progression                                                         Compute survival rate

  Cancer state                                             Check for residual cancer                              Compute disease-free survival rate                                                   

  Type of recurrence                                       Check for cancer progression                           Compute recurrence rate                                                              

  Duration of survival                                     Check for cancer progression                           Compute survival rate                                                                

  Date of initial recurrence                               Check for cancer progression                           Compute disease-free survival rate and recurrence rate                               

  Date of final contact                                    Check for cancer progression                           Use in follow-up investigation                                                       
  -------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------------------------ -------------------------------------------------

![Study Flow Chart](APJCP-20-3173-g001){#F1}

![Comparison of the Distribution of Cancer Registry Items by Category](APJCP-20-3173-g002){#F2}
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Results
=======

*Identification of potential cancer registry items by comparing foreign and domestic data*

After excluding "management information," 26, 556, 79, and 52 items were collected from the KCCR, the NAACCR (2013), the NHS, and the ENCR (2015), respectively. The registries in the US and UK, and the ENCR collected more information about treatment, staging and prognostic factors, and follow-up than did KCCR. However, the JACR and CCA collected information regarding fewer items than did KCCR ([Table 2](#T2){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}).

With reference to the items in the KCCR, the following foreign and Korean cancer registry items were collected in five categories (total number of items not shown) (Supplementary Tables). Under the category of "demographic information," foreign cancer registries collected information on the place of birth, race or ethnicity, and type of residence (urban/rural). Some hospitals also collected information regarding marital status, telephone number, weight, and height. Under the category of "cancer diagnosis," the KCCR and foreign cancer registries collected information about similar items in general. Some foreign and Korean hospital registries additionally collected information about symptoms, medical history, diagnostic date of multiple primary cancer, pathologic results, tumor marker, drinking history, cancer size, and family history.

Under the category of "cancer treatment," the KCCR, foreign cancer registries, and Korean hospital registries all collected information about surgery, chemotherapy, radiation therapy, immune therapy, and hormone therapy. Some foreign and Korean hospital registries additionally collected information about the date of treatment and treatment outcomes; particularly, the NAACCR collected information about re-admission within 30 days.

Under the category of "staging and prognostic factors," cancer registries commonly collected information about staging (SEER, Extent of Disease) and Tumor, Node, and Metastasis (TNM) stage. Information about the pediatric stage was only collected by the NAACCR, while information about CS was collected by the NAACCR and Korean registries. At one Korean hospital, information about toxic substances, ionizing radiation, exposure to second-hand smoke and exposure to asbestos were also collected.

Under the category of "follow-up," the KCCR only collected information regarding the date of death and cause of death, while foreign cancer registries collected more detailed information, including that regarding vital status, survival period, type of recurrence, and physicians. Korean hospital registries also collected additional information on follow-up items other than the date and cause of death.

*Selection of additional cancer registry items based on consensus among cancer registration workers*

[Table 3](#T3){ref-type="table"} shows the results of the need and priority of additional cancer registry items reported by 272 cancer registration workers out of 500 participants (54.4%).

Under the category of "demographic information," items regarding date of birth (n=86, 31.6%), country of birth (n=86, 31.6%), and race (n=78, 28.7%) were reported to be "highly needed." Put in order of priority they were country of birth, date of birth, type of residence (urban/rural), place of birth, race, ethnicity, and marital status at diagnosis.

Under the category of "cancer diagnosis," more than 50% of the participants reported that information regarding the type of cancer, smoking history, concurrent cancer, medical history, date of multiple cancer diagnosis, and symptoms was highly needed. Placed in order of priority they included medical history, symptoms, type of cancer, date of multiple cancer diagnosis, concurrent cancer, smoking history, type of pathologic tests.

Under the category of "cancer treatment," more than 40% of the participants reported that information regarding treatment outcomes, date of treatment, treatment code, chemotherapy, radiation therapy, and palliative treatment were highly needed. Put in order of priority, they were the date of treatment, treatment code, chemotherapy, radiation therapy, treatment outcomes, palliative treatment, reason for non-treatment.

Under the category of "staging and prognostic factors," more than 50% of the participants reported that information regarding pathologic TNM stage and clinical TNM stage were highly needed. Put in order of priority they were pathologic TNM stage, clinical TNM stage, TNM version used in the cancer registry, pre-treatment CS, post-treatment CS, CS-site of metastasis, and pediatric cancer staging.

Under the category of "follow-up information," more than 50% of the participants reported that information regarding survival (n=139, 51.1%) and duration of survival (n=139, 51.1%) were highly needed. Put in order of priority, they were survival, duration of survival, cancer state, date of final contact, date of initial recurrence, age at final contact, and type of recurrence.

*Selection of additional cancer registry items and use of information based on consensus among cancer experts*

[Table 4](#T4){ref-type="table"} shows the results reported by 10 cancer experts out of 36 participants. Under the category of "demographic information," the experts reported that information regarding date of birth was the most needed, followed by race, country of birth, place of birth, and marital status at diagnosis. Particularly, the experts stated that information regarding date of birth is needed when there is a limitation with using resident registration numbers. The experts stated that information regarding race, country of birth, and place of birth needed to be collected for research on the cancer incidence trends among foreigners, as there is an increasing foreign population in Korea.

Under the category of "cancer diagnosis," the experts reported that information regarding the type of cancer (initial, recurrent) was the most important, followed by those of smoking history, date of multiple primary cancer diagnosis, concurrent cancer, medical history, symptoms, and types of pathologic tests. Information regarding the date of multiple primary cancer diagnosis and type of cancer (initial, recurrent) were needed to classify multiple primary cancers. Information regarding types of pathologic tests was needed to confirm the accuracy of diagnosis and reliability of pathologic tests.

Under the category of "cancer treatment," the experts reported that information regarding date of treatment, the agent used for chemotherapy, radiation therapy, treatment code, palliative treatment, treatment outcomes, and reason for non-treatment need to be collected. Information regarding treatment codes and date of treatment are important for evaluating treatment outcomes; for radiation therapy, information about completion of treatment, as opposed to total treatment dose and area, is needed. Further, the experts stated that information regarding chemotherapy is needed to evaluate the efficacy of chemotherapy agents. Some experts stated that it would be possible to estimate the percentage of cancer patients participating in a clinical trial for a novel drug if relevant information was collected.

Under the category of "staging and prognostic factors," the experts reported that information regarding TNM stage, CS, CS-site specific factor, comorbidity, and complications need to be collected. The experts agreed that these items are required to evaluate the efficacy of treatment.

Under the category of "follow-up information," the experts reported that information regarding survival, cancer state, type of recurrence, duration of survival, date of initial recurrence, and date of final contact need to be collected. Information regarding the date of final contact is needed to verify the accuracy of the follow-up data, and those of survival and duration of survival are needed to calculate the survival rate. Information regarding the date of initial recurrence is needed to compute the disease-free survival rate, and that regarding the type of recurrence is needed to determine whether the recurrence is local or remote and whether metastasis occurred.

Discussion
==========

This study suggested additional data items to be collected to enhance the usefulness of KCCR data, based on foreign cancer registries and the specified large hospitals in Korea. A comparison of foreign cancer registry items and the KCCR registry items revealed that they collected information regarding similar items for "demographic information" and "cancer diagnosis," but the KCCR collected information regarding fewer items under the categories of "treatment," "staging and prognostic factors," and "follow-up." Under the category of "demographic information," foreign cancer registries collected information such as place of birth, race, and type of residence (urban/rural). Under the category of "cancer diagnosis," the KCCR and foreign cancer registries mostly collected information regarding similar items. In the NAACCR, information regarding pathologic results were emphasized for collection. Under the category of "staging and prognostic factors," the KCCR and foreign cancer registries collected information about the summary stage and TNM stage. Information about pediatric staging was collected only in the NAACCR, while that regarding CS was only collected in the NAACCR and Korean registry. Under the category of "follow-up," the KCCR only collected information regarding date of death and cause of death, while the foreign cancer registries collected information about recurrence, survival, address at follow-up, and physician in charge. In Australia, cancer registries in each state differ by the inclusion of some additional items depending on the characteristics of the state. Korea could follow this example, by maintaining common items and adding additional items relevant to the region and type of cancer to establish a differentiated database.

The NAACCR institutes cancer registry certification for each state, which could also be applied in Korea. A program to certify data collection and management in hospital cancer registries could be developed as a measure to enhance the quality of the data. Hospital cancer registries collect data either directly from patients' medical records or from an established database based on a system that analyzes discharged patients.

In this study, we investigated additional items, information of which could be collected by the KCCR, because hospital registries would collect more information than required by the KCCR for research purposes. Under the category of "demographic information," hospital registries collected information regarding marital status, telephone number, weight, and height at diagnosis. Under the category of "cancer diagnosis," information regarding symptoms, smoking history, diagnostic date of multiple cancers, tumor marker, and cancer size and family history were collected. Under the category of "cancer treatment," information about the date of treatment, palliative care at this facility, detailed radiation therapy data, and treatment outcomes were collected. Under the category of "staging and prognostic factors," information regarding TNM and other staging information and comorbidity/complication data were collected. Under the category of "follow-up," more detailed information, such as those of cause of death, survival period, and cancer status (complete remission, partial remission) were collected with more active follow-up. As shown here, hospital cancer registries are collecting and utilizing more detailed data than the KCCR, so it would be less challenging for the KCCR to expand the number of registry items to be collected in the future. Further, the inclusion of additional cancer registry items by linking with the hospital database could improve the quality and usefulness of the KCCR data. However, additional studies are needed to measure the increased work burden imposed upon cancer registration workers, which could limit the expansion of cancer registry items, and to investigate possible solutions to this problem.

In the present study, MRAs and cancer experts mostly agreed on the registry items that should be added, and there was a consensus among the two groups regarding the need to add more items to the national cancer registration dataset. In the survey of the need for additional items, which are registered in foreign cancer registries but not in the KCCR, and priority of registration, hospital MRAs and cancer experts reported that information regarding date of birth, country of birth, and race are highly needed items under the category of "demographic information." Considering the current environment with an increased entry of foreigners into the country, these additional items could be used as sources of data for relevant policymaking and research. Under the category of "cancer diagnosis," the experts agreed that information regarding type of cancer, medical history, and smoking history should be collected. This finding corroborates an American study that investigated the need for additional cancer registry items and confirmed the need to collect additional smoking-related information (Zachary et al., 2015). Under the category of "cancer treatment," the experts reported the need to collect data regarding the date of treatment, chemotherapy agent, and radiation therapy. These items could be collected from the electronic medical record systems and medical record management systems of hospitals. Thus, the standard for each item and collection procedure could be suggested based on a discussion among hospital personnel, KCCR, and researchers. Under the category of "staging," the experts reported the need to collect information regarding TNM stage, CS, and comorbidity/complication. It is beneficial to collect information regarding both TNM and CS in terms of potentially complementing each other when either is omitted. Moreover, the experts suggested the need to improve the current collection of staging information. Although information regarding comorbidity can be collected from medical record management systems, its scope is too wide and vague; thus, data regarding comorbidity should be collected based on a clear criterion or a link to another source. Under the category of "follow-up," the experts reported the need to add information regarding survival, cancer state, type of recurrence, and duration of survival. The experts determined that linking the cancer registry data with other data sources, such as big healthcare data, would enable an indirect collection of follow-up data. Furthermore, it is important to improve the entry of cancer-related information into medical records to enhance the accuracy of cancer registry data, calling for the implementation of continuous and active quality improvement activities. More detailed information regarding diagnosis, staging and prognostic factors, treatment, and follow-up must be collected to expand cancer research using cancer registry data. However, a further subdivision of these categories may limit the collection and completeness of data. Thus, it is important to collect key data and add additional items for cancer research and monitoring.

National cancer registries enable researchers to not only produce cancer statistics and identify time-series trends, but also to identify the causes of cancer and assess treatment effects by collecting demographic, socioeconomic, and clinical data. It is also possible to partially expand the scope of cancer registry data by linking them to external data sources. Therefore, the expansion of cancer registry items could provide information for computing novel statistical indices and enable the production of more advanced cancer statistics in Korea.
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